| Market Capitalization (Millions $) |
1,383 |
| Shares
Outstanding (Millions) |
510 |
| Employees |
12 |
| Revenues (TTM) (Millions $) |
- |
| Net Income (TTM) (Millions $) |
9 |
| Cash Flow (TTM) (Millions $) |
0 |
| Capital Exp. (TTM) (Millions $) |
0 |
Business Description
Chemomab Therapeutics Ltd is a clinical-stage biotechnology company that is committed to developing novel and effective solutions for inflammatory and fibrotic diseases. The company was founded in 2014 and is headquartered in Israel. Its core platform technology is based on the development of highly selective monoclonal antibodies, which have the potential to create breakthrough therapies for a wide range of diseases.
Chemomab Therapeutics' lead product candidate, CM-101, is a first-in-class monoclonal antibody targeting the CCL24 protein, which is a key player in the inflammatory process. The antibody has shown highly promising results in preclinical and early clinical trials, demonstrating its potential to treat a wide range of inflammatory diseases, including fibrosis, arthritis, asthma, and allergies.
The company's development strategy is focused on leveraging its core technology platform to develop a suite of highly selective monoclonal antibodies targeting various inflammation and fibrosis pathways. This approach allows the company to identify the best target proteins for a particular disease and develop highly effective and safe therapies with reduced side effects.
Chemomab Therapeutics has a highly experienced management team with a strong track record of developing and commercializing novel therapies. The company is backed by a group of prominent investors and has partnerships with several leading pharmaceutical companies.
In summary, Chemomab Therapeutics Ltd is a highly innovative biotechnology company focused on developing novel and effective solutions for inflammatory and fibrotic diseases. The company's proprietary technology platform and highly selective monoclonal antibodies have the potential to create life-changing therapies for patients suffering from these debilitating conditions.
Company Address: 10 Habarzel Street, Building C, 10th Floor Tel Aviv 6158101
Company Phone Number: 77-331-0156 Stock Exchange / Ticker: NASDAQ CMMB
|
2.69% 